These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 31100782)

  • 1. Molecular Targets of Genistein and Its Related Flavonoids to Exert Anticancer Effects.
    Chae HS; Xu R; Won JY; Chin YW; Yim H
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31100782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.
    Shin SB; Woo SU; Chin YW; Jang YJ; Yim H
    J Cell Physiol; 2017 Oct; 232(10):2818-2828. PubMed ID: 27861885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plumbagin inhibits the proliferation and survival of esophageal cancer cells by blocking STAT3-PLK1-AKT signaling.
    Cao YY; Yu J; Liu TT; Yang KX; Yang LY; Chen Q; Shi F; Hao JJ; Cai Y; Wang MR; Lu WH; Zhang Y
    Cell Death Dis; 2018 Jan; 9(2):17. PubMed ID: 29339720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
    Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
    Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin synergizes with Polo-like kinase 1 inhibitors to induce apoptosis in rhabdomyosarcoma.
    Stehle A; Hugle M; Fulda S
    Cancer Lett; 2015 Aug; 365(1):37-46. PubMed ID: 25917079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1.
    Mao Y; Xi L; Li Q; Cai Z; Lai Y; Zhang X; Yu C
    Oncol Rep; 2016 Jul; 36(1):49-56. PubMed ID: 27220401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas.
    Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K
    Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
    Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
    Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM; Shi Y; Quan J
    ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
    Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
    Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of synthetic lethality of PLK1 inhibition and microtubule-destabilizing drugs.
    Hugle M; Belz K; Fulda S
    Cell Death Differ; 2015 Dec; 22(12):1946-56. PubMed ID: 26024389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
    De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
    Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
    Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
    Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
    Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
    J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
    Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
    Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.
    Lee KS; Burke TR; Park JE; Bang JK; Lee E
    Trends Pharmacol Sci; 2015 Dec; 36(12):858-877. PubMed ID: 26478211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
    Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation.
    Ismail IA; Kang KS; Lee HA; Kim JW; Sohn YK
    Eur J Pharmacol; 2007 Dec; 575(1-3):12-20. PubMed ID: 17706963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.